In An Organic Compound Patents (Class 424/1.65)
-
Patent number: 8652438Abstract: There is provided a central nervous system labelling composition for intranasal administration for the purpose of labelling the central nervous system from the olfactory epithelium by way of the olfactory bulb and by means of intranasal administration. Additionally, there is provided a method of non-invasively labelling the central nervous system by way of an administration route that entails little transferability to the entire body. Furthermore, there is provided a screening method using a central nervous system labelling composition for intranasal administration.Type: GrantFiled: April 12, 2011Date of Patent: February 18, 2014Assignee: Canon Kabushiki KaishaInventors: Tsuyoshi Nomoto, Kohei Watanabe, Taichi Shintou, Takeshi Miyazaki, Toshio Tanaka, Yuhei Nishimura, Yasuhito Shimada
-
Patent number: 8647643Abstract: The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response.Type: GrantFiled: September 26, 2009Date of Patent: February 11, 2014Assignee: Cadila Pharmaceuticals, LtdInventors: Bakulesh Mafatlal Khamar, Indravadan Ambalal Modi, Rajiv Indravadan Modi
-
Publication number: 20140037542Abstract: A compound that includes a quaterrylene dye moiety as core, and a dendrimeric shell. For example, the compound may comprise at least four dendronized polyamides covalently attached to a quaterrylene dye. Also disclosed is a compound, or a pharmaceutically acceptable salt or ester thereof, comprising A(G)x, wherein: A comprises a quaterrylene dye; G comprises at least one functionalized dendrimeric structure; and x is 2 to 16. The compounds may be used for in methods for monitoring a therapeutic or diagnostic agent in a subject, or for treating a subject by administering the compound to the subject.Type: ApplicationFiled: July 31, 2013Publication date: February 6, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Mingfeng Bai, Pin Shao
-
Publication number: 20140037541Abstract: A method for imaging is providing, including administering a teboroxime species to an adult human subject, administering T1-201-thallous chloride to the subject performing a teboroxime species SPECT imaging procedure of the teboroxime species on a region of interest (ROI) of the subject, and, after administering the teboroxime species, performing a T1-201-thallous chloride SPECT imaging procedure of the T1-201-thallous chloride on the ROI. Administering the teboroxime species and the T1-201-thallous chloride and performing the teboroxime species and the T1-201-thallous chloride SPECT imaging procedures comprise administering the teboroxime species and the T1-201-thallous chloride and performing the teboroxime species and the T1-201-thallous chloride SPECT imaging procedures during a time period having a duration of no more than 30 minutes. Other embodiments are also described.Type: ApplicationFiled: June 10, 2013Publication date: February 6, 2014Applicant: BIOSENSOR INTERNATIONAL GROUP LTD.Inventors: Benny Rousso, Dalia Dickman
-
Publication number: 20140030189Abstract: Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.Type: ApplicationFiled: June 12, 2013Publication date: January 30, 2014Inventors: Ajay Purohit, Thomas D. Harris, Heike S. Radeke, Simon P. Robinson, Ming Yu, David S. Casebier, Michael T. Azure
-
Patent number: 8636978Abstract: Cyclized peptide compounds containing the NGR motif of formula (I) or a pharmaceutically-acceptable salt thereof are disclosed. Compositions comprising the cyclized peptide compounds and methods of their use are also disclosed.Type: GrantFiled: June 15, 2009Date of Patent: January 28, 2014Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Bradford J. Wood, Matthew Dreher, Ayele H. Negussie
-
Patent number: 8632753Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.Type: GrantFiled: December 20, 2010Date of Patent: January 21, 2014Assignees: Bracco Suisse SA, Dyax Corp.Inventors: Hong Fan, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski, Aaron K. Sato, Sharon Michele Walker, Daniel T. Dransfield
-
Patent number: 8632751Abstract: The invention provides a scanning suspension comprising a particle which is capable of at least in part disturbing a magnetic field, wherein said particle comprises a diameter of at least 1 ?m, and use thereof for obtaining a scanning image. Preferably, said particle comprises holmium and a composition capable of essentially maintaining its structure during irradiation. A particle of the invention is suitable for preparing a kit of parts, comprising a diagnostic and a therapeutic composition which both comprise particles of the invention with essentially the same chemical structure, wherein said therapeutic composition is more radioactive than said diagnostic composition. Said kit of parts is especially suitable for treatment of a tumor. First, the distribution of a particle of the invention within an individual can be determined with a scanning image obtained with said scanning composition.Type: GrantFiled: December 29, 2004Date of Patent: January 21, 2014Assignees: Universitair Medisch Centrum Utrecht, Universiteit Utrecht Holding B.V.Inventors: Johannes Franciscus W. Nijsen, Alfred Dirk van het Schip, Bernard Antoni Zonnenberg
-
Patent number: 8632748Abstract: Compositions of high specific activity 117mSn with specific activity of greater than 100 Ci/g Sn and methods of producing the same. The method includes exposing 116Cd to an ?-particle beam of sufficient incident kinetic energy and duration to convert a portion of the 116Cd to 117mSn to form an irradiated material. The irradiated material is dissolved to form an intermediate solution containing 117mSn and 116Cd. The 117mSn is separated from the 116Cd to yield high specific activity 117mSn.Type: GrantFiled: August 23, 2012Date of Patent: January 21, 2014Assignee: Clear Vascular, Inc.Inventors: Nigel Raymond Stevenson, Ian Martin Horn
-
Patent number: 8628750Abstract: Provided herein are compounds or conjugates useful for diagnostic imaging and/or therapeutic purposes. Each compound or conjugate comprises a ligand for the chemokine receptor CXCR4 and a detectable label. The ligand has a binding affinity for the CXCR4 receptor, measured as IC50 in the presence of 125I-CPCR4, of 250 nM or lower, and the ligand comprises a cyclic oligopeptide moiety having the motif B-Arg or B-(Me)Arg within the cyclic moiety, wherein B is a basic amino acid, a derivative thereof, or phenylalanine, provided that the motif is B-Arg when B is a N?-methyl derivative of a basic amino acid.Type: GrantFiled: February 27, 2007Date of Patent: January 14, 2014Assignee: Technische Universitat MunchenInventors: Hans Jürgen Wester, Norman Koglin, Markus Schwaiger, Horst Kessler, Burkhardt Laufer, Oliver Demmer, Martina Anton
-
Patent number: 8628753Abstract: Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted ? conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended ? conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo.Type: GrantFiled: September 28, 2010Date of Patent: January 14, 2014Assignees: Emory University, Georgia Tech Research CorporationInventors: Niren Murthy, W. Robert Taylor, Kousik Kundu, Sarah F. Knight, Sungmun Lee
-
Patent number: 8623328Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.Type: GrantFiled: August 9, 2012Date of Patent: January 7, 2014Assignee: Shanghai Cancer InstituteInventors: Wenxin Qin, Haitao Zhang, Yanjun Yu, Haiyan You, Shengli Yang, Jianren Gu, Gang Huang, Shile Sheng, Tao Chen
-
Patent number: 8623323Abstract: The present invention relates to thickened beverage compositions. More particularly the invention relates to beverage compositions thickened for the management of dysphagia. More particularly this invention relates to the production of thickened beverages by a dispensing machine that is also capable of dispensing non-thickened beverages.Type: GrantFiled: February 11, 2011Date of Patent: January 7, 2014Assignee: Simply Thick, LLCInventor: John L. Holahan
-
Patent number: 8617515Abstract: The present invention relates to methods for myelin basic protein detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the agent, and determining myelination in the subject by detecting binding to myelin basic protein. Methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using an agent with specific binding to myelin basic protein are also provided as is a kit containing the agent or its derivatives for use in detecting myelin basic protein.Type: GrantFiled: June 4, 2009Date of Patent: December 31, 2013Assignee: General Electric CompanyInventors: Cristina Abucay Tan Hehir, Tiberiu Mircea Siclovan, Nicole Evelyn Barnhardt, Kenneth Michael Fish, Randall Lee Carter, Bruce Fletcher Johnson
-
Patent number: 8617518Abstract: The present application discloses compositions and methods of synthesis and use of 68Ga, 18F or 19F labeled molecules of use in PET or MRI imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a chelating moiety, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 68Ga, 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. In more preferred embodiments, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment.Type: GrantFiled: March 26, 2013Date of Patent: December 31, 2013Assignee: Immunomedics, Inc.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Patent number: 8617516Abstract: The present invention provides a substantially non-lytic, non-cytotoxic anchor peptide that is capable of stably inserting into lipid membranes. In particular, the invention provides nanoparticles comprising stably inserted anchor peptides, which may be conjugated to a variety of different cargo complexes.Type: GrantFiled: October 22, 2010Date of Patent: December 31, 2013Assignee: Washington UniversityInventors: Samuel A. Wickline, Hua Pan, Neelesh R. Soman, Gregory M. Lanza, Paul H. Schlesinger
-
Patent number: 8613905Abstract: The invention provides an agent comprising an amino acid sequence for use in a method of diagnosis of a synucleinopathic disease.Type: GrantFiled: August 29, 2008Date of Patent: December 24, 2013Assignee: United Arab Emirates UniversityInventor: Omar El-Agnaf
-
Patent number: 8613904Abstract: The present disclosure concerns methods of administering and detecting a distinguishable agent in a sample from and assessing the condition of an organ in a subject. In a particular embodiment, the present invention concerns methods of detecting and comparing the cholate shunt, in a subject, preferably in a subject with chronic hepatitis C. In certain embodiments, the methods may comprise obtaining a sample from a subject such as a blood or saliva sample after administering an oral and intravenous dose of a distinguishable agent such as cholate and analyzing the sample clearance of the distinguishable agent from the subject and comparing the clearance levels in order to assess hepatic health. In another embodiment, the methods may comprise analyzing a sample from a subject for the presence of a distinguishable agent such as cholate and applying information obtained from analyzing the presence of the distinguishable agent to determine a treatment for a medical condition of the subject.Type: GrantFiled: January 26, 2006Date of Patent: December 24, 2013Assignee: The Regents of the University of ColoradoInventors: Gregory Thomas Everson, Michael Anthony Martucci
-
Publication number: 20130336888Abstract: A dendrimer conjugate according to Formula (I), or its pharmaceutically acceptable salt, or solvate thereof: and complexes of Formula I conjugates with metals radionuclides of elements such as rhenium, technetium, yttrium, lutetium and others to provide a complex for imaging tissues or for the radiotherapeutic treatment of cancer tissue. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.Type: ApplicationFiled: December 6, 2011Publication date: December 19, 2013Inventors: John W. Babich, John L. Joyal, Craig Zimmerman
-
Publication number: 20130336887Abstract: The invention provides methods and compositions, e.g., for tumor imaging and therapy.Type: ApplicationFiled: March 11, 2013Publication date: December 19, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventor: President and Fellows of Harvard College
-
Publication number: 20130336889Abstract: A nanoparticle for detecting or treating a tumor is provided. The nanoparticle includes a plurality of polymer backbones and at least one first detectable substance, of which each of the polymer backbones includes a hydrophobic region, a hydrophilic region and a chelating region, and the first detectable substance is bound to the chelating region of the polymer backbone. The hydrophobic regions of the polymer backbones form a core block, and the hydrophilic regions of the polymer backbones form a shell block surrounding the core block. A method for detecting or treating a tumor using the nanoparticle is also provided.Type: ApplicationFiled: June 14, 2012Publication date: December 19, 2013Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Ming-Jium Shieh, Cheng-Liang Peng, Tsai-Yueh Luo
-
Patent number: 8603435Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. The present invention represents a step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma.Type: GrantFiled: January 12, 2009Date of Patent: December 10, 2013Assignee: STC.UNMInventors: Yubin Miao, Haixun Guo
-
Patent number: 8603436Abstract: Disclosed are Drug Delivery Molecules (DDMs) which both facilitate functional imaging, as by PET, MRI or SPECT, and create a biological effect and methods of their use. These DDMs which are variously designed to target specific receptors, internalized and then function biologically, as for purposes of cell destruction or therapy.Type: GrantFiled: March 11, 2011Date of Patent: December 10, 2013Inventor: Gerhart Graupner
-
Publication number: 20130323170Abstract: The present invention relates to compositions and methods for preparing radiopharmaceutical compounds in high chemical-purity and isotopic-purity. The present invention provides polymer-bound precursors to radiopharmaceutical compounds that can be converted to radiopharmaceutical compounds in one step. In a preferred embodiment, a radiopharmaceutical precursor is bound to a polymeric support via a prosthetic group comprising an alkenyl-tin bond. The radiopharmaceutical precursor is converted to a radiopharmaceutical compound in one step involving cleavage of the alkenyl-tin bond and incorporation of a radioisotope to form the radiopharmaceutical compound. Importantly, the polymeric support containing the toxic tin by-product can be easily removed from the radiopharmaceutical compound by filtration. The present invention can be used to install a large number of different radioisotopes. In a preferred embodiment, the radioisotope is 211At, 123I, or 131I.Type: ApplicationFiled: April 3, 2013Publication date: December 5, 2013Inventors: Duncan Hunter, M. Karen J. Gagnon
-
Publication number: 20130315827Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.Type: ApplicationFiled: May 28, 2013Publication date: November 28, 2013Applicants: Fluoropharma, Inc., The General Hospital CorporationInventors: David R. Elmaleh, Timothy M. Shoup, Hongning Fu
-
Publication number: 20130315822Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.Type: ApplicationFiled: December 21, 2012Publication date: November 28, 2013Applicant: Lantheus Medical Imaging, Inc.Inventor: Lantheus Medical Imaging, Inc.
-
Patent number: 8591865Abstract: A method for measuring a glomerular filtration rate of a mammalian subject comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the vascular system of the mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the glomerular filtration rate.Type: GrantFiled: November 15, 2010Date of Patent: November 26, 2013Assignee: Pharmacophotonics, Inc.Inventors: Exing Wang, Daniel Meier, Robert Bunch, Bruce Molitoris, Ruben Sandoval, Matthew Rubin, Erinn Sheridan
-
Publication number: 20130309168Abstract: The invention provides a family of agents that target bacterial infection, which can be used as imaging agents or therapeutic agents. The agents can be used to image sites of bacterial infection as well as other physiological processes in a subject.Type: ApplicationFiled: March 15, 2013Publication date: November 21, 2013Applicant: VisEn Medical, Inc.Inventor: VisEn Medical, Inc.
-
Patent number: 8586006Abstract: The present invention relates generally to methods for identifying and using organ-specific proteins and transcripts. The present invention further provides compositions comprising organ-specific proteins and transcripts encoding the same, detection reagents for detecting such proteins and transcripts, and diagnostic panels, kits and arrays for measuring organ-specific proteins/transcripts in blood, biological tissue or other biological fluid.Type: GrantFiled: August 9, 2007Date of Patent: November 19, 2013Assignees: Institute for Systems Biology, Integrated Diagnostics, Inc.Inventors: Leroy Hood, Patricia M. Beckmann, Richard Johnson, Marcello Marelli, Xiaojun Li
-
Publication number: 20130302246Abstract: The present application provides compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reaction for rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.Type: ApplicationFiled: February 7, 2013Publication date: November 14, 2013Inventor: The General Hospital Corporation
-
Publication number: 20130302245Abstract: Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.Type: ApplicationFiled: April 17, 2013Publication date: November 14, 2013Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: David J. YANG, Chang-sok OH, Saady KOHANIM, Dongfang YU, Richard MENDEZ, E. Edmund KIM
-
Patent number: 8580229Abstract: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.Type: GrantFiled: October 23, 2012Date of Patent: November 12, 2013Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: William E. Klunk, Chester A. Mathis, Jr.
-
Publication number: 20130295009Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof;Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Inventors: Torbjorn LUNDSTEDT, Anna SKOTTNER, Elisabeth SEIFERT
-
Patent number: 8574543Abstract: A method including isotope labeling of a newly synthesized protein in a sufficient quantity such that a newly synthesized protein spectra and the pre-existing protein spectra are sufficiently separated. A further method including determining a ratio of a new and a pre-existing protein from mass spectra obtained by using mass spectrometry. In this method a resultant spectrum may be presented as integrated peak heights for a corresponding mass to charge ratio in the “centroid” mode.Type: GrantFiled: December 11, 2008Date of Patent: November 5, 2013Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Wai-Nang P. Lee, Guishan Xiao
-
Patent number: 8574546Abstract: Substituted aryl-boron compounds comprising at least one 18F atom, as illustrated by the formula (I), where at least one of Y1 or Y2 is 18F and A1 is a substituted aromatic ring, with G1-5 being, independently, C or N, and where the substitutents of the aromatic ring or polycyclic moiety (other than boron) comprise at least one electron-withdrawing group (EWG), providing that sigma total (?total) for all substituents on the aromatic ring or polycyclic moiety except B is about 0.06 or more when said at least one EWG is positioned ortho to B, or about 0.2 or more when no EWG is positioned ortho to B. The compounds include neutral (N=1) and ionic borate (N=2) embodiments. The compounds are useful as positron emission tomography (PET) imaging agents.Type: GrantFiled: July 24, 2008Date of Patent: November 5, 2013Assignee: The University of British ColumbiaInventors: David Perrin, Richard Ting, Christopher Overall
-
Patent number: 8568693Abstract: The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2, (b) cMet, (c) guanylyl cyclase or (d) IGF1R. The imaging agent is suitable for radioisotope or optical imaging in vitro or preferably in vivo.Type: GrantFiled: February 26, 2009Date of Patent: October 29, 2013Assignee: GE Healthcare ASInventors: Antonios Danikas, Clifford Smith, Ian A Wilson
-
Patent number: 8568689Abstract: The invention relates to contrast agents for detection of the Urokinase Plasminogen Activator Receptor (uPAR). More specifically the invention relates to contrast agents comprising a peptidic vector binding to the uPAR, labelled with an imageable moiety.Type: GrantFiled: September 28, 2005Date of Patent: October 29, 2013Assignee: GE Healthcare ASInventors: Alan Cuthbertson, Bente E. Arbo
-
Patent number: 8562951Abstract: Neurophysiologic information such as quantitative electroencephalography (QEEG) is used in a method for classifying, diagnosing, and treating physiologic brain imbalances. Neurophysiologic information is also used to guide sample selection in clinical tests for psychopharmacologic drug candidates. Finally, neurophysiologic information is used for remotely assessing and treating patients with physiologic brain imbalances.Type: GrantFiled: May 25, 2010Date of Patent: October 22, 2013Assignee: CNS ResponseInventors: Stephen Suffin, W. Hamlin Emory
-
Patent number: 8562948Abstract: Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic reagents, and methods of making and use thereof.Type: GrantFiled: March 31, 2011Date of Patent: October 22, 2013Assignee: The Regents of the University of CaliforniaInventors: Sandra Blaj Moore, Zelda Goodman
-
Patent number: 8562945Abstract: Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.Type: GrantFiled: December 4, 2009Date of Patent: October 22, 2013Assignee: Molecular Insight Pharmaceuticals, Inc.Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, John Marquis, Genliang Lu, Jian-cheng Wang, Shawn Hillier
-
Patent number: 8562946Abstract: A new system accomplishes easy, interchangeable production of multiple PET radiopharmaceuticals through the use of a simplified eluant-only generator and a kit based synthesis technique employing lyophilized or freeze dried ligand. Thus, by simply switching the lyophilized ligand vial kit, any number of 62Cu-labeled radiopharmaceuticals (62Cu-ligand) can be interchangeably synthesized with only one 62Zn/62Cu generator.Type: GrantFiled: September 16, 2011Date of Patent: October 22, 2013Assignee: Proportional Technologies, Inc.Inventor: Jeffrey L. Lacy
-
Patent number: 8562953Abstract: A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)i)j or SP-DX-Z-L)i)j, wherein, S is cyclosilane moiety with j silicon oxygen residual groups, and j is not less than 2; P is CH2CH2Ol, and l is not less than 1; D is a C3-30 dendritic moiety having n oxygen residue, and n is not less than 3; X is C3-30 moiety having bi-functional groups; Z is a C3-20 moiety having a plurality of functional group; and L is a metal cation.Type: GrantFiled: October 2, 2012Date of Patent: October 22, 2013Assignee: Industrial Technology Research InstituteInventors: Dhakshanamurthy Thirumalai, Chin-I Lin, Shian-Jy Wang
-
Publication number: 20130266513Abstract: Methods for detecting or ruling out a meningioma in a patient using a phenylbenzothiazole derivative or a stilbene derivative or a biphenylalkyne derivative, and a medical imaging technique such as positron emission tomography/computed tomography are disclosed.Type: ApplicationFiled: October 11, 2011Publication date: October 10, 2013Inventors: Geoffrey B. Johnson, Val J. Lowe, Mark A. Nathan, Joseph E. Parisi
-
Patent number: 8551446Abstract: A coating for a medical device, particularly for a drug eluting stent, is described. The coating includes a polyacetal-based polymer.Type: GrantFiled: September 18, 2007Date of Patent: October 8, 2013Assignee: Advanced Cardiovascular Systems, Inc.Inventor: Ni Ding
-
Patent number: 8551447Abstract: A bifunctional compound with a monosaccharide and a N2S2 ligand, and more particularly, a bifunctional compound with a N2S2 ligand and aminohexylacetyl galactosamine (ah-GalNAc4) is provided. A method for preparing the bifunctional compound with a monosaccharide and a N2S2 ligand is also provided, including activating a carboxyl group in an organic ligand, reacting the activated carboxyl group with a galactopyranoside through amidation, and then hydrolyzing. The bifunctional compound of the present invention is widely useful in nuclear medicine for preparation of liver imaging agents for assisting in correct diagnosis of diseases.Type: GrantFiled: April 15, 2011Date of Patent: October 8, 2013Assignee: Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: Show-Wen Liu, Cheng-Hsien Lin, Yu Chang, Cheng-Fang Hsu, Tsyh-Lang Lin
-
Patent number: 8551453Abstract: The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands of the invention.Type: GrantFiled: December 29, 2004Date of Patent: October 8, 2013Assignee: The Regents of the University of CaliforniaInventors: Kenneth N. Raymond, Stephane Petoud, Jide Xu
-
Publication number: 20130259805Abstract: The invention provides compounds and a method for imaging aggregated ?-synuclein, e.g., Lewy bodies or Lewy neurites, in a tissue or organ.Type: ApplicationFiled: November 11, 2011Publication date: October 3, 2013Applicant: THE GENERAL HOSPITAL CORPORATIONInventor: Brian Bacskai
-
Patent number: 8545809Abstract: The present application discloses compositions and methods of synthesis and use of 18F or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.Type: GrantFiled: December 12, 2011Date of Patent: October 1, 2013Assignee: Immunomedics, Inc.Inventors: Christopher A. D'Souza, William J. McBride, David M. Goldenberg
-
Patent number: 8540968Abstract: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.Type: GrantFiled: December 20, 2005Date of Patent: September 24, 2013Assignee: Cellectar, Inc.Inventors: Jamey Weichert, Marc Longino, Anatoly Pinchuk
-
Patent number: 8535641Abstract: The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers.Type: GrantFiled: March 2, 2005Date of Patent: September 17, 2013Assignee: Cellectar, Inc.Inventors: Jamey Weichert, Marc Longino, Anatoly Pinchuk